Thomas Andersen's picture

Thomas Andersen

PhD Candidate
  • E-mailthomas.andersen@uib.no
  • Visitor Address
    Haukelandsveien 28
    Armauer Hansens hus
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). Procollagen type 1 N-terminal propeptide is associated with adverse outcome in acute chest pain of suspected coronary origin. Frontiers in Cardiovascular Medicine.
  • Show author(s) (2022). Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine. 1-9.
  • Show author(s) (2019). Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial. European Heart Journal: Acute Cardiovascular Care. 313-322.
  • Show author(s) (2019). C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology. 2402-2410.
  • Show author(s) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A9149. The novel Wnt-Pathway inhibitor podogan is not associated with all-cause mortality or cardiovascular outcome in patients admitted with suspected acute coronary syndrome. .
  • Show author(s) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A12013. Procollagen type-1 N-terminal propeptide, a collagen synthesis biomarker, is associated with adverse clinical outcome in patients with nsuspected acute coronary syndrome. .

More information in national current research information system (CRIStin)